DEVELOPING A HOLISTIC GLP-1 STRATEGY

We take an evidence-based approach to GLP-1 drugs, working with our partners to develop individualized strategies that promote clinically appropriate use and consider total cost of care, long-term value and member health outcomes.

PRESS RELEASES

GLP-1 year-2 real-world data

Prime Therapeutics LLC/Magellan Rx Management, LLC (Prime/MRx) continues to lead the industry with a new analysis of real-world integrated pharmacy and medical claims data, which shows 85% of individuals who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for weight loss were no longer taking the drug after two years. This analysis is a follow-up to research presented by Prime/MRx in 2023, which found that 71% of individuals were no longer taking these drugs for weight loss at one year, representing a further 14% point decrease in persistence in just one year.

CLINICAL PERSPECTIVES

The evolution of GLP-1s

When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend.² So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program. You can learn more about the latest GLP-1 trends, the drug pipeline and ways to capitalize on new opportunities.

Clinical insights

Holistic solutions for weight management

Obesity has grown in prevalence over recent decades, with nearly 73.1% of adults in the U.S. who are either overweight or obese. In addition to the health impact obesity can have, it’s also costing the health care system almost $173B per year. We’ve published a new white paper outlining where we are today and how things are shaping up for the future, demystifying trends like GLP-1s and providing our expert perspective on what it takes to deliver a whole-person approach to sustainable weight management.

KEEPWELL™

Next-level cardiometabolic support

Conditions like obesity, diabetes, hypertension and high cholesterol can compound if left unchecked, causing serious and costly health problems. KeepWell offers a personalized and effective path to wellness for your members, driving better outcomes across the cardiometabolic spectrum.

PODCASTS

Hear from our GLP-1 experts

Year-one data

REAL-WORLD ANALYSIS

The impact of GLP-1s

Glucagon-like peptide-1 agonists, or GLP-1s, have historically been used to manage type 2 diabetes. But there has also been a substantial increase in people using these drugs for weight loss, causing demand to skyrocket. In a recent study, Prime Therapeutics and Magellan Rx found only 27% of individuals were still using GLP-1s for weight loss a year after they began treatment – and revealed increased health care costs of $7,727 per person.1 As GLP-1s continue to transform the health care landscape, we offer clinical experts who help our partners stay on the forefront of this dynamic trend, delivering trusted, evidence-based insights.

Stay on top of the latest news

Regular updates from our newsroom

In the news

July 18, 2024

8 updates on GLP-1s

Becker’s Hospital Review

1 Internal analysis, 2023

2 Internal analysis, 2023, based on GLP-1 list prices at time of publishing, including but not limited to Wegovy and Zepbound

3 Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9. Medication and weight-loss is for people living with type 2 diabetes and completing 1 year. Medication reduction refers to the percent of total diabetes prescriptions eliminated, excluding metformin.

4 McKenzie AL, Athinarayanan SJ, McCue JJ, Adams RN, Keyes M, McCarter JP, Volek JS, Phinney SD, Hallberg SJ. Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study. Nutrients. 2021; 13(3):749.